| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/06/2011 | US20110004000 Mitotic Kinesin Inhibitor |
| 01/06/2011 | US20110003876 Tetrahydroindoles Having Sphingosine-1-Phosphate Receptor Activity |
| 01/06/2011 | US20110003874 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 01/06/2011 | US20110003873 Pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases |
| 01/06/2011 | US20110003860 Hydroxyl compounds and compositions for cholesterol management and related uses |
| 01/06/2011 | US20110003858 Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| 01/06/2011 | US20110003853 Metalloproteinase Inhibitors |
| 01/06/2011 | US20110003851 Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
| 01/06/2011 | US20110003847 Prasugrel Salts with Improved Properties |
| 01/06/2011 | US20110003845 Substituted azabicyclic compounds and the use thereof |
| 01/06/2011 | US20110003844 Regulation of cardiac contractility and heart failure propensity |
| 01/06/2011 | US20110003843 Novel compounds derived from indole and pharmaceutical compositions containing them |
| 01/06/2011 | US20110003834 Production method and production apparatus for a high theobromine-containing composition |
| 01/06/2011 | US20110003832 NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS |
| 01/06/2011 | US20110003831 N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 01/06/2011 | US20110003824 Caspase Inhibitors and Uses Thereof |
| 01/06/2011 | US20110003823 Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| 01/06/2011 | US20110003815 Diphenyl substituted cycloalkanes |
| 01/06/2011 | US20110003812 Human Adam-10 Inhibitors |
| 01/06/2011 | US20110003810 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| 01/06/2011 | US20110003808 Octahydroquinolizines for antidiabetic treatment |
| 01/06/2011 | US20110003807 Thiazole derivatives |
| 01/06/2011 | US20110003806 Heteroaryls and uses thereof |
| 01/06/2011 | US20110003804 Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure |
| 01/06/2011 | US20110003801 Benzimidazole derivatives useful as trpm8 channel modulators |
| 01/06/2011 | US20110003800 Benzimidazole derivatives useful as trpm8 channel modulators |
| 01/06/2011 | US20110003795 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands |
| 01/06/2011 | US20110003792 Anti-inflammatory agents |
| 01/06/2011 | US20110003785 Fused Thiazole Derivatives As Kinase Inhibitors |
| 01/06/2011 | US20110003774 Compounds having anti-proliferative properties |
| 01/06/2011 | US20110003766 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists |
| 01/06/2011 | US20110003756 C5a Receptor Antagonists |
| 01/06/2011 | US20110003755 Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof |
| 01/06/2011 | US20110003750 Human 3 relaxin |
| 01/06/2011 | US20110003746 Protein variants |
| 01/06/2011 | US20110003743 Stem cell derived factors for treating pathologic conditions |
| 01/06/2011 | US20110003388 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells |
| 01/06/2011 | US20110003360 Delta-6 desaturase and uses thereof |
| 01/06/2011 | US20110003351 Delta-5 desaturase and uses thereof |
| 01/06/2011 | US20110003019 Extract from palm leaves and a method for producing the same |
| 01/06/2011 | US20110003008 Mesenchymal stem cell particles |
| 01/06/2011 | US20110002999 Biopolymer System for Tissue Sealing |
| 01/06/2011 | US20110002995 Pharmaceutical composition for the treatment and prevention of cardiac disease |
| 01/06/2011 | US20110002994 Method of regulating the th17 pathway and its associated metabolic impact |
| 01/06/2011 | US20110002987 Nicorandil Carriers with Enhanced Stability |
| 01/06/2011 | US20110002983 Compound |
| 01/06/2011 | US20110002924 Tweak receptor agonists as anti-angiogenic agents |
| 01/06/2011 | US20110002910 Therapeutic agents comprising pro-apoptotic proteins |
| 01/06/2011 | US20110002908 Treatment of a-galactosidase a deficiency |
| 01/06/2011 | US20110002906 Purification and Isolation of Recombinant Oxalate Degrading Enzymes and Spray-Dried Particles Containing Oxalate Degrading Enzymes |
| 01/06/2011 | US20110002894 Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
| 01/06/2011 | US20110002893 Diagnosis and treatment of congenital heart defects using nell1 |
| 01/06/2011 | US20110002888 Albumin Fusion Proteins |
| 01/06/2011 | US20110002876 Multimeric VLA-4 Antagonists Comprising Polymer Moieties |
| 01/06/2011 | CA2766884A1 Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| 01/06/2011 | CA2766073A1 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists |
| 01/06/2011 | CA2764425A1 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
| 01/05/2011 | EP2270107A1 Compounds for Dual Photodiagnosis and Therapy |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270042A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270041A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2269988A2 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
| 01/05/2011 | EP2269653A1 Composition for stabilizing -blocker, and transdermally absorbable preparation comprising the composition |
| 01/05/2011 | EP2269634A2 Antigenic polypeptides |
| 01/05/2011 | EP2269621A1 Agents for maturing, normalizing or stabilizing blood vessels and wrinkle-preventing and improving agents |
| 01/05/2011 | EP2269620A1 Therapeutic uses of dunaliella powder |
| 01/05/2011 | EP2269614A1 Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation |
| 01/05/2011 | EP2269593A1 Transdermally absorbable preparation |
| 01/05/2011 | EP2269578A2 Generation of Therapeutic Microfoam |
| 01/05/2011 | EP2268812A1 Inhibitors of stim1 for the treatment of cardiovascular disorders |
| 01/05/2011 | EP2268644A1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| 01/05/2011 | EP2268641A2 Heterocyclic compounds as adenosine receptor antagonist |
| 01/05/2011 | EP2268638A1 Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| 01/05/2011 | EP2268637A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/05/2011 | EP2268634A2 Processes for the preparation of bosentan and related compounds using novel intermediates |
| 01/05/2011 | EP2268625A1 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof |
| 01/05/2011 | EP2268606A1 4-dimethylaminobutyric acid derivatives |
| 01/05/2011 | EP2268600A1 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions |
| 01/05/2011 | EP2268320A1 Image-guided therapy of myocardial disease: composition, manufacturing and applications |
| 01/05/2011 | EP2268304A2 Methods for treating acute myocardial infarction |
| 01/05/2011 | EP2268302A2 Bmp-7 for use in treating vascular sclerosis |
| 01/05/2011 | EP2268299A1 Compositions and method for reducing scar formation in wound healing |
| 01/05/2011 | EP2268277A1 Use of flavonoide compounds for the propyhylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases |
| 01/05/2011 | EP2268141A1 Compounds and method for reducing uric acid |
| 01/05/2011 | EP2001483B1 Use of cholest-4-ene-3-one derivatives to obtain a cytoprotective medicine |
| 01/05/2011 | EP1763338B1 Oral sustained release formulation of tedisamil with gastric retention properties |
| 01/05/2011 | EP1661890B1 Ppar-activating compound and pharmaceutical composition containing same |
| 01/05/2011 | EP1619498B1 Method of screening remedy for heart disease and medicinal composition for treating heart disease |
| 01/05/2011 | EP1558256B1 Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury |
| 01/05/2011 | EP1542692B1 Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| 01/05/2011 | EP1493034B1 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 01/05/2011 | EP1446381B1 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP1437043B1 Rat model with overexpression of regucalcin |
| 01/05/2011 | EP1365778B1 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 01/05/2011 | EP1128814B1 Aerosols comprising nanoparticle drugs |
| 01/05/2011 | CN201692349U Amlodipine polypharmacy valsartan capsule tablet |
| 01/05/2011 | CN1788748B Detection method of injection formulation containing raw material herb red sage root or red sage |
| 01/05/2011 | CN101939321A Production method and production device for composition having high content of theobromine |